Articles related to DRUG DISCOVERIES
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
The recent phase 3 trial of vorasidenib in patients with grade 2 IDH-mutant glioma has demonstrated significant improvements in progression-free survival and time to next intervention. Explore the detailed findings to understand how this oral inhibitor could become a vital part of the treatment regimen for this challenging condition.
Neurology August 21st 2023
Changes to the SCLC Treatment Landscape Stirs Up Hope for Oncologists
The landscape of small cell lung cancer treatment is undergoing significant transformation with the advent of immune checkpoint inhibitors. This shift not only provides new therapeutic options but emphasizes the importance of a comprehensive team approach, including early detection strategies, and holds the promise for enhanced patient prognosis.
Oncology, Medical August 1st 2023
New Targeted Treatments Emerge for Gastric and Esophageal Cancer
The field of gastric and esophageal cancer treatment is witnessing remarkable advancements through targeted therapies and immunotherapies. Explore the latest clinical trials and discoveries that are redefining the standard of care for these traditionally difficult-to-treat cancers.
Gastroenterology August 1st 2023
“Unprecedented” PFS Benefit with Selinexor in p53 Wild-Type Endometrial Cancer
Selinexor has demonstrated an extraordinary extension in progression-free survival in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to the recent findings from the SIENDO study.
Obstetrics & Gynecology August 1st 2023
Allopurinol May Cut Risk for Neurodegenerative Diseases
Discover the potential of xanthine dehydrogenase/oxidase blockers, such as allopurinol, in reducing the risk of neurodegenerative diseases. This large-scale study reveals intriguing associations and sets the stage for future research.
Clinical Pharmacology June 30th 2023